New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
17:40 EDTAPRIApricus Biosciences CEO Bassam Damaj resigns, CFO Steve Martin named interim CEO
Apricus Biosciences announced that Bassam Damaj, Ph.D., has resigned as a director, president, and CEO of the company and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The changes are effective immediately. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO whose experience is expected to include significant background in commercial operations within the pharmaceutical industry.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
07:13 EDTAPRIApricus Biosciences awarded U.S. patent for RayVa
Apricus Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348. The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa™ product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use